Median effective dose of intravenous nalmefene for preventing sufentanil-induced cough in children aged 1–6 years: a prospective randomized controlled trial - Quiz - MDSpire

Determining the Median Effective Dose of Intravenous Nalmefene for the Prevention of Sufentanil-Induced Cough in Pediatric Patients Aged 1 to 6: A Prospective Randomized Controlled Study

  • By

  • Chao Wang

  • Fan Wang

  • Lijing Li

  • Xiaoxue Wang

  • Lanxin Qiao

  • Fang Wang

  • July 20, 2026

Share

Original Source(s)

Median effective dose of intravenous nalmefene for preventing sufentanil-induced cough in children aged 1–6 years: a prospective randomized controlled trial

  • by Chao Wang, Fan Wang, Lijing Li, Xiaoxue Wang, Lanxin Qiao, Fang Wang

  • July 20, 2026

Related Content

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

The efficacy of tonsillectomy in the management of PFAPA syndrome: a systematic review and meta-analysis

Gram-negative bloodstream infections in pediatric patients: antimicrobial resistance and factors associated with mortality